SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

M&A: An Overlooked ETF Investing Zone of AI Boom?

AI-driven data-center dealmaking is surging. ETFs like MNA, IAI, KBWB, CHAT offer ways to tap the M&A boom tied to AI infrastructure.

ETFs to Watch as Global M&A Momentum Returns

Global M&A activity hits $1.29T in Q3, fueled by rate-cut hopes and record U.S. bank deals, signaling strong momentum for dealmaking.

Defender Capital, a long-term shareholder of STAAR Surgical Company, on Tuesday expressed opposition to the firm’s proposed acquisition by Alcon Inc.Defender Capital owns 1.5% of STAAR’s common stock. “The proposed sale of STAAR to Alcon for $28 per share significantly undervalues the company, especially when considering the STAAR board of directors' rejection of Alcon's previous offer for $58 per share in cash only sixteen months ago,” the shareholder said.Defender Capital further <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/defender-capital-opposes-staar-surgicals-proposed-sale-to-alcon-302577240.html">added</a> that it sees no compelling reason to sell STAAR at this time, with recent optimistic projections and outlook. The shareholder also expressed disappointment at the company board, alleging that the proposed transaction is ‘ill-advised’ and does not reflect STAAR’s prospects as a standalone company.Shares of <a href="https://stocktwits.com/symbol/STAA">STAAR Surgical</a> Company traded nearly 2% lower on Tuesday. On Stocktwits, retail sentiment around STAA stock stayed within the ‘bearish’ territory while message volume remained at ‘normal’ levels.Defender Capital is not the only one to oppose the proposed acquisition. Last month, Hong Kong-headquartered investment management firm Yunqi Capital, which holds a 5.1% stake in STAAR, <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-shareholder-yunqi-capital-opposes-proposed-merger-with-alcon/chDQFDHR32a">alleged</a> in a letter to other shareholders that it would not necessarily be opposed to a potential merger of the two companies at an appropriate price or on other appropriate terms, but opposed the deal on the terms announced in August.Before Yunqi, Broadwood Partners, L.P., and its affiliates also announced their intention to vote against the proposed acquisition. Broadwood is STAAR’s largest shareholder, owning 27.5% of the company’s outstanding common shares.STAAR is a manufacturer of phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Alcon said in early August that the companies have entered into a definitive merger agreement under which Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash. The transaction is expected to close in about six to 12 months and represents a total equity value of approximately $1.5 billion, it added.STAA stock is up 8% this year and down approximately 23% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's Note: The story has been updated to reflect Broadwood Partners' accurate stake in STAAR Surgical Company.

Global stock market chart and trading board - stock photo

STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company

Defender Capital, which owns 1.5% of STAAR’s common stock, highlighted STAAR’s board of directors' rejection of Alcon's previous offer of $58 per share in cash.

Equity

Defender Capital, which owns 1.5% of STAAR’s common stock, highlighted STAAR’s board of directors' rejection of Alcon's previous offer of $58 per share in cash.


M&A Deals Thriving in 2025: ETFs in Focus

M&A deals are booming in 2025 despite fewer transactions -- megadeals, AI bets and Fed cuts may fuel ETFs like MNA, IAI, KBWB & CHAT.

H&amp;E Equipment Services (HEES) stock garnered retail attention on Monday after the company’s fourth-quarter earnings beat Wall Street’s estimates.On Friday, the company reported adjusted earnings of $36.1 million, or $0.99 per share, for the fourth quarter. According to Koyfin data, analysts, on average, expected the company to post $0.78 per share.The equipment rental company reported quarterly sales of $384.1 million, compared with Wall Street’s estimated $372.5 million.The company’s rental revenue rose 0.9% to $283 million compared to the same period last year.It reported fourth-quarter net income of $32.8 million, or $0.90 per share, compared to $53.5 million, or $1.47 per share, last year.The company said that average rental rates fell 1.1% from the year-ago quarter and 0.3% sequentially.At the end of the fourth quarter, the original equipment cost of the company’s rental fleet was about $2.9 billion, a 5.5% rise compared to last year.H&amp;E Equipment said its rental equipment sales fell 30.1% to $28.4 million, while new equipment sales more than doubled to $20.9 million.Last week, H&amp;E Equipment Services agreed to <a href="https://stocktwits.com/news-articles/markets/equity/h-and-e-equipment-stock-hits-record-high-after-better-offer/ch5YwIfRv1">be acquired</a> by Herc Holdings for $104.89 per share after outbidding United Rentals.Herc had said that its proposal represents a 14% premium to United Rentals’ cash-capped consideration.Retail sentiment on Stocktwits remained in the ‘extremely bullish’ (85/100) territory while retail chatter was ‘high.’<figure class="image"><img style="aspect-ratio:807/178;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/HEES_Feb_24_e55e3a3923.JPG" alt="HEES’s Sentiment Meter and Message Volume as of 02:21 a.m. ET on Feb. 24, 2025 | Source: Stocktwits" width="807" height="178"><figcaption>HEES’s Sentiment Meter and Message Volume as of 02:21 a.m. ET on Feb. 24, 2025 | Source: Stocktwits</figcaption></figure>Over the past week, <a href="https://stocktwits.com/symbol/HEES">H&amp;E Equipment shares</a> have gained 11%, while over the past 12 months, the stock has gained 81%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/esab-stock-receives-evercore-upgrade-after-recent-selloff-retail-stays-bullish/chdP80BRx5">ESAB Stock Receives Evercore Upgrade After Recent Selloff, Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Road construction machinery on the construction of highway S6, Koszalin, Poland. (Image Courtesy: Getty Images)

H&E Equipment Services Stock In Spotlight After Q4 Earnings Beat, Retail Stays Ecstatic

The equipment rental company reported quarterly sales of $384.1 million, compared with Wall Street’s estimated $372.5 million.

MNA
IndexIQ ETF Trust - IQ Merger Arbitrage ETF

Feed

News

Sentiment

Fundamentals

Info

Latest MNA News

MNAIndexIQ ETF Trust - IQ Merger Arbitrage ETF